Foresee Genomics is developing a DNA testing system for cancer patients that combines molecular biology and computational analysis. The companys tests are designed to provide physicians with the genetic data needed for determining treatment options. Foresee Genomics procedure requires low-cost equipment and is intended to be performed at the point of care, in hospitals or local clinics. The nanopore sequencing platform is significantly inexpensive in comparison to all other NGS platform. The combined system of Foresee Genomic and the nanopore sequencer is an end-to-end solution for genomic diagnostics which is accurate and affordable.